KOL | David E SchteingartDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan | Department of Internal Medicine, University of Michigan Medical Center, Ann ... |
KOL Resume for David E Schteingart
| Year | |
|---|---|
| 2015 | Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan |
| 2013 | Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA |
| 2012 | Division of Metabolism, Endocrinology and Diabetes, Endocrine Oncology Program, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA. |
| 2010 | Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Rm 5570, MSRB 2, 1150 West Medical Center Dr, Ann Arbor MI 48109, USA. |
| 2009 | Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA. University of Michigan Medical School, BSRB 1502, 109 Zina Pitcher Place, 48109-2200, Ann Arbor, MI, USA |
| 2006 | Endocrinology and Metabolism (D.E.S.) Ann Arbor, Michigan 48109 Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan |
| 2005 | Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA. |
| 2003 | Department of Internal Medicine (DES), University of Michigan Medical School, Ann Arbor, Michigan, USA |
| 2002 | Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical School, 1150 West Medical Center Dr., Ann Arbor, MI 48109, USA |
| 2001 | University of Michigan Medical School, Ann Arbor, MI Departments of Internal Medicine (D.E.S., R.S.B., D.A.A.), Ann Arbor, Michigan 48109 |
| 2000 | University of Michigan, Ann Arbor, USA |
| 1999 | Department of and Department of Internal Medicine (DES), University of Michigan Medical School, Ann Arbor, Michigan, USA |
| 1997 | Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, MI 48109-0678, USA, US |
| 1996 | Division of Endocrinology and Metabolism, University of Michigan Medical Center, Ann Arbor, MI, USA |
| 1995 | Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109-0722, U.S.A. USIntenal Medicine, Medical School, University of Michigan, Ann Arbor, MI 48109 |
| 1993 | Departments of Internal Medicine, Pharmacology, and Pathology, Medical School and College of Pharmacy, University of Michigan, 48109, Ann Arbor, MI, USA |
| 1992 | Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, U.S.A |
| 1991 | Professor of Internal Medicine, Interim Chief, Division of Endocrinology and Metabolism, University of Michigan Medical Center, Ann Arbor, Michigan |
| 1989 | Professor of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan Medical School, Ann Arbor, Michigan |
| 1987 | Third Department of Internal Medicine, Kyushu University |
| 1986 | David E. Schteingart, M.D., is Professor, Department of Internal Medicine, School of Public Health, University of Michigan, USA From the Departments of Pathology, Surgery (Section of Neurosurgery), and Internal Medicine (Division of Endocrinology and Metabolism), The University of Michigan Medical Center, Ann Arbor, Michigan |
| 1981 | From the Department of Medicine, Sections of Allergy and Endocrinology, University of Michigan School of Medicine Ann Arbor, Mich., USA |
| 1980 | Neuro psychological Laboratory, University of Michigan, 1111 East Catherine Street, Ann Arbor, Michigan 48109 |
| 1979 | Ann Arbor, Michigan, USA |
| 1974 | Department of Internal Medicine, Section on Endocrinology and Metabolism, University of Michigan, Ann Arbor, MI 48104 |
| 1973 | From the Section of Urology, Department of Surgery and Sections of Endocrinology and Metabolism, and Nuclear Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan |
| 1972 | Department of Internal Medicine Section on Endocrinology and Metabolism University of Michigan Ann Arbor, MI 48104 |
| 1968 | Departments of Internal Medicine (Section of Endocrinology and Metabolism) and Pathology of the University of Michigan Medical Center, Ann Arbor, Mich |
| 1965 | Department of Internal Medicine, Division of Endocrinology and Metabolism and The Metabolism Research Unit University of Michigan, Ann Arbor, Mich. |
David E Schteingart: Influence Statistics
| Concept | World rank |
|---|---|
| mitometh mitotane | #1 |
| hf volume | #1 |
| adrenal cancer | #1 |
| mitotane 3hrelease | #1 |
| assay βhydroxylation | #1 |
| presence βhydroxylation | #1 |
| mitometh mitomethtreated dogs | #1 |
| adrenal concentration mitometh | #1 |
| abnormal alternative processing | #1 |
| radioactivity hydrolysates | #1 |
| adrenalytic activity | #1 |
| nervosa thyroid | #1 |
| adrenal cancer conference | #1 |
| mitometh | #1 |
| ectopic pomc | #1 |
| adrenal transformations | #1 |
| adrenal venogram | #1 |
| hippocampal formation volume | #1 |
| hormonal carcinoma humans | #1 |
| assay mitotane | #1 |
| track ball traces | #1 |
| binding mitotane | #1 |
| hplc 3hrelease assay | #1 |
| hydroxylation isomerism | #1 |
| pomc nonpituitary | #1 |
| drugs medical treatment | #1 |
| analog mitotane | #1 |
| cortisol mitotane | #1 |
| mitometh toxicity | #1 |
| gh secretion decrease | #1 |
| cushings syndrome validity | #1 |
| verbal nonverbal subtests | #1 |
| secreting testosterone | #1 |
| patients hf volume | #1 |
| 131i19iodocholesterol iodine radioisotopes | #1 |
| patient ethmoid sinuses | #1 |
| mitotane β | #1 |
| cortisol secretion decrease | #1 |
| major pathway isomers | #1 |
Open the FULL List in Excel | |
Prominent publications by David E Schteingart
Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion
[ PUBLICATION ]
Obesity and starvation have opposing affects on normal physiology and are associated with adaptive changes in hormone secretion. The effects of obesity and starvation on thyroid hormone, GH, and cortisol secretion are summarized in Table 1. Although hypothyroidism is associated with some weight gain, surveys of obese individuals show that less than 10% are hypothyroid. Discrepancies have been reported in some studies, but in untreated obesity, total and free T4, total and free T3, TSH ...
| Known for Thyroid Hormone | Cortisol Secretion | Anorexia Nervosa | Gh Increase | Total Free |
PurposeInsulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma. As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine the safety, tolerability, pharmacokinetics, and effects on endocrine markers of figitumumab in patients with adrenocortical carcinoma.MethodsFigitumumab was administered on day 1 of each 21-day ...
| Known for Adrenocortical Carcinoma | Figitumumab Patients | Solid Tumors | Growth Hormone | 1 Receptor |
Cushing's syndrome is a complex endocrine condition with potential serious complications if untreated or inadequately treated. Transsphenoidal surgery with resection of a pituitary adenoma is successful in 75 - 80% of patients, but approximately 20 - 25% show persistence of Cushing's, and a similar proportion may experience recurrence within 2 - 4 years post-op. When surgery fails, medical treatment can temporarily suppress excessive cortisol production and ameliorate its clinical ...
| Known for Medical Treatment | Cushings Syndrome | Patients Cushing | Cortisol Secretion | Pituitary Adenoma |
Outcome of Transsphenoidal Surgery for Cushing Disease: A Single-Center Experience Over 32 Years
[ PUBLICATION ]
BACKGROUND: Transsphenoidal surgery is the standard approach for treating Cushing disease. Evidence is needed to document effectiveness.
OBJECTIVE: To analyze results of transsphenoidal surgery in 276 consecutive patients, including 19 children.
METHODS: Medical records were reviewed for patients treated initially with surgery for Cushing disease from 1980 to 2012. Radiographic features, pathology, remissions, recurrences, and complications were recorded. Patients were categorized for ...
| Known for Cushing Disease | Transsphenoidal Surgery | Remission Rates | Patients Microadenomas | Pituitary Adenoma |
Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma
[ PUBLICATION ]
Mitotane is an important adrenalytic drug for the treatment of adrenal cancer whose use is limited by toxicity. Reports from another laboratory indicated that a methylated homolog of Mitotane (Mitometh) tested in guinea pigs possessed comparable adrenalytic activity but was less toxic than Mitotane. This observation prompted us to undertake a comparative study of these two drugs on the basis that Mitometh may be a superior agent for the treatment of adrenal cancer. Preliminary studies in ...
| Known for Adrenal Cortex | Carcinoma Cell | Activity Mitotane | Treatment Dogs | Humans Hydrocortisone |
Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome
[ PUBLICATION ]
Patients with chronic hypercortisolemia due to Cushing's syndrome (CS) exhibit cognitive dysfunction. Because glucocorticoid excess is associated with hippocampal damage in animals, and the hippocampus participates in learning and memory, we explored the relationships between hippocampal formation (HF) volume, memory dysfunction, and cortisol levels in 12 patients with CS. After magnetic resonance imaging, HF volume was determined using digital sum of track ball traces of dentate gyrus, ...
| Known for Cortisol Levels | Hippocampal Formation | Verbal Recall | Cushings Syndrome | Memory Dysfunction |
Management of patients with adrenal cancer: recommendations of an international consensus conference
[ PUBLICATION ]
Adrenocortical carcinomas are rare, highly malignant tumors that account for only 0.2% of deaths due to cancer. Given the limited number of patients seen in most medical centers with this diagnosis, series usually reported are small and clinical trials not randomized or blinded. In an attempt to answer important questions concerning the management of patients with adrenal cancer, a consensus conference was organized and held at the University of Michigan in Ann Arbor, MI, 11-13 September ...
| Known for Adrenal Cancer | Management Patients | Preclinical Studies | Adrenocortical Carcinomas | Ann Arbor |
EEG sleep in cushing's disease and cushing's syndrome: comparison with patients with major depressive disorder
[ PUBLICATION ]
Because patients with Cushing' syndrome (CS) and Major depressive disorder (MDD) share features of hypercortisolism and the depressive syndrome, we compared electro-encephalographic (EEG) sleep in patients with pituitary-ACTH-dependent Cushing's syndrome (Cushing's disease, CD), patients with ACTH-independent Cushing's syndrome (AICS), patients with major depressive disorder (MDD), and normal subjects. There were substantial similarities in the abnormal polysomnography profiles of ...
| Known for Patients Cushing Syndrome | Depressive Disorder | Cushings Disease | Sleep Rem | Pituitary Adrenal |
Shifted inferior frontal laterality in women with major depressive disorder is related to emotion-processing deficits
[ PUBLICATION ]
BACKGROUND: Facial emotion perception (FEP) is a critical human skill for successful social interaction, and a substantial body of literature suggests that explicit FEP is disrupted in major depressive disorder (MDD). Prior research suggests that weakness in FEP may be an important phenomenon underlying patterns of emotion-processing challenges in MDD and the disproportionate frequency of MDD in women. Method Women with (n = 24) and without (n = 22) MDD, equivalent in age and education, ...
| Known for Major Depressive Disorder | Inferior Frontal | Women Mdd | Leftward Bias | Emotion Processing |
Patients with Cushing's syndrome (CS) frequently have sleep complaints. We evaluated sleep polysomnographically in 22 patients, including 17 with pituitary-ACTH-dependent Cushing's disease (CD) and five with CS from an adrenal tumor. Data were compared to healthy controls of comparable age. Seven patients (32%) demonstrated at least mild sleep apnea (> or = 9.4 events/hour), and four of 22 (18%) had > or = 17.5 events/hour. The apneic CD and CS patients had a trend for a greater ...
| Known for Sleep Apnea | Cushing Syndrome | Rem Latency | Normal Subjects | Rapid Eye Movement |
A 49-year old woman with a 5-year history of Cushing's syndrome was evaluated. Biochemical measurements revealed high cortisol and adrenocorticotropic hormone (ACTH) levels consistent with the ACTH-dependent type of Cushing's syndrome. However, the source of ACTH seemed to be autonomous as she demonstrated abnormal feedback control, with lack of response to metyrapone and high coses of dexamethasone. A search for an ectopic ACTH-secreting nonpituitary neoplasm was unsuccessful. ...
| Known for Ectopic Pituitary Adenoma | Cushings Syndrome | Sphenoid Sinus | Adrenocorticotropic Hormone | Pituitary Gland |
Depressed Mood and Other Psychiatric Manifestations of Cushing's Syndrome: Relationship to Hormone Levels
[ PUBLICATION ]
Thirty-five consecutive patients with Cushing's syndrome were studied prospectively prior to treatment. A consistent constellation of psychiatric disturbances was found, including impairments in affect (depressed mood and crying), cognitive functions (decreased concentration and memory), and vegetative functions (decreased libido and insomnia). A statistically significant relationship was found between the overall psychiatric disability rating and cortisol and ACTH level. The ...
| Known for Depressed Mood | Psychiatric Manifestations | Hormone Levels | Cushings Syndrome | Depressive Disorder |
Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease
[ PUBLICATION ]
BACKGROUND: Decreased hippocampal volume is observed in patients with Cushing's syndrome and other conditions associated with elevated cortisol levels, stress, or both. Reversibility of hippocampal neuronal atrophy resulting from stress occurs in animals. Our study investigated the potential for reversibility of human hippocampal atrophy.
METHODS: The study included 22 patients with Cushing's disease. Magnetic resonance brain imaging was performed prior to transsphenoidal ...
| Known for Hippocampal Atrophy | Cushing Disease | 22 Patients | Resonance Imaging | Human Hippocampus |
Key People For Adrenal Cancer
David E Schteingart:Expert Impact
Concepts for whichDavid E Schteingarthas direct influence:Adrenal cancer, Adrenocortical carcinoma, Adrenal scintigraphy, Cortisol secretion, Cushings syndrome, Depressed mood, Neuroendocrine tumors, Cushing syndrome.
David E Schteingart:KOL impact
Concepts related to the work of other authors for whichfor which David E Schteingart has influence:Adrenocortical carcinoma, Cushing syndrome, Hippocampal volume, Pituitary adenomas, Cortisol levels, Adrenal cortex, Chronic stress.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |